Nuwellis CEO Mike McCormick Targets Pediatric Expansion and Revenue Growth
Event summary
- Mike McCormick becomes Nuwellis CEO on June 30, 2026, succeeding John Erb, who transitions to Chairman.
- Q1 2026 revenue grew 26% YoY with gross margin improving to 70.1%, up 14 percentage points.
- Nuwellis aims to expand Aquadex indication to pediatric patients weighing as low as 5 kg via FDA engagement.
- Acquisition of Rendiatech adds automated kidney function monitoring to Nuwellis' cardiorenal platform.
The big picture
Nuwellis is doubling down on pediatric and critical care markets amid leadership transition. The strategic focus on expanding Aquadex's reach and integrating Rendiatech's diagnostics aligns with broader trends in precision fluid management and ICU monitoring. With improving margins and revenue growth, the company aims to strengthen its position in cardiorenal medicine while managing operational costs.
What we're watching
- Regulatory Approval
- Whether Nuwellis can secure FDA approval to expand Aquadex use in lower-weight pediatric patients.
- Integration Success
- How effectively Nuwellis integrates Rendiatech's technology into its existing cardiorenal platform.
- Operational Efficiency
- The pace at which Nuwellis reduces cash burn while maintaining growth investments.
Related topics